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Abstract
Background: Liver fibrosis is the result of continuous liver injury stemming from different etiological factors.
Bile duct injury induces an altered expression of TGF-β, which has an important role in liver fibrosis because this
cytokine induces the expression of target genes such as collagens, PAI-1, TIMPs, and others that lead to
extracellular matrix deposition. Smad7 is the principal inhibitor that regulates the target gene transcription of the
TGF-β signaling. The aim of the study was to determine whether Smad7 mRNA expression correlates with the
gene expression of TGF-β, Col I, Col III, Col IV, or PAI-1 in liver fibrosis secondary to bile duct injury (BDI).
Results: Serum TGF-β concentration was higher in BDI patients (39 296 pg/ml) than in liver donors (9008 pg/
ml). Morphometric analysis of liver sections showed 41.85% of tissue contained fibrotic deposits in BDI patients.
mRNA expression of Smad7, Col I, and PAI-1 was also significantly higher (P < 0.05) in patients with BDI than in
controls. Smad7 mRNA expression correlated significantly with TGF-β concentration, Col I and Col III
expression, and the amount of fibrosis.
Conclusion: We found augmented serum concentration of TGF-β and an increase in the percentage of fibrotic
tissue in the liver of BDI patients. Contrary to expected results, the 6-fold increase in Smad7 expression did not
inhibit the expression of TGF-β, collagens, and PAI-1. We also observed greater expression of Col I and Col III
mRNA in BDI patients and significant correlations between their expression and TGF-β concentration and Smad7
mRNA expression.
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Background
Liver fibrosis is caused mainly by alcohol consumption
and viral hepatitis, and it is an important health problem
throughout the world. Bile duct injury (BDI) is also an
important etiological factor because it can cause second-
ary biliary cirrhosis and long-term disability, and it
increases the risk of death threefold[1,2]. BDI can occur as
a complication of cholecystectomy, an elective surgery for
cholelithiasis. The introduction of laparoscopy has
increased the BDI incidence to 0.3-1.0%, which is higher
than that associated with open cholecystectomy (0.1-
0.3%) [3-5].
BDI causes obstruction of bile ducts, which results in
cholestasis. BDI increases the concentrations of serum
aminotransferases, bilirubin, and alkaline phosphatase
(AP). As the obstruction proceeds, the accumulation of
biliary salts in the canalicular membrane produces dilata-
tion of bile ducts, which may rupture and form bile
deposits. Mononuclear cells infiltrate into the portal tracts
and bile ducts proliferate, leading to degeneration of
hepatocytes and periportal fibrosis deposition[3,6-8].
Transforming growth factor-β (TGF-β) is a multifunc-
tional cytokine involved in the regulation of cell prolifer-
ation, differentiation, extracellular matrix (ECM)
production, wound healing, and tissue repair. TGF-β plays
an important role in liver fibrogenesis because it triggers
the overexpression and deposition in the ECM of mole-
cules such as PAI-1, TIMP-1, Col I, Col III, Col IV,
tenascin, fibronectin, and Smad7 [9-14].
Smad7 is the principal inhibitor that regulates the target
gene transcription of the TGF-β signaling[15,16]. Smad7
exerts its inhibitory effect by its association with activated
TGF-β I receptor and inhibition of Smad2/3 phosphoryla-
tion.
Smad7 has been used in experimental models to block
TGF-β effects in different disorders [17-19]. Dooley et
al[20] and Tahashi et al[16] demonstrated that Smad7
expression was low in experimental liver fibrosis, and this
event allows liver scar formation. Some investigators have
used gene therapy[16,20,21] with an adenoviral vector
containing Smad7 complementary DNA (cDNA) and a
Chinese herbal medicine[22], to treat fibrosis and cirrho-
sis in different experimental models. However, there are
no reports on Smad7 in human liver fibrosis. In this con-
text, the aim of our study was to determine whether
Smad7 mRNA expression correlates with the expression of
TGF-β,  Col I,  Col III,  Col IV,  and PAI-1 genes in BDI
patients and to compare these relationships with controls
(liver donors).
Methods
Patients and samples
Eighteen patients were included in this study. Fourteen
patients had extrahepatic BDI caused by open or laparo-
scopic cholecystectomy that had been reconstructed surgi-
cally. These patients were recruited from Centro Médico
General de Occidente, and 4 liver donors with normal
liver histology, recruited from the Hospital Civil de Guad-
alajara, were included as a control group. The serum con-
centrations of alanine aminotransferase (ALT), aspartate
aminotransferase (AST), direct bilirubin (DB), and AP
were measured before the reconstruction surgery. Serum
was obtained from a peripheral blood (PB) sample with-
out anticoagulant from each patient and control. Liver
biopsy specimens were obtained during bile duct recon-
struction surgery. None of the patients or controls had a
clinical history of previous liver disease or alcohol or drug
abuse. The study protocol was in accordance to the ethical
guidelines of the World Medical Association Declaration
of Helsinki (adopted by the 52nd WMA General Assembly,
Edinburgh, Scotland, October 2000) and was approved
by the ethical committee of the institutions. Informed
written consent was obtained from each patient and con-
trol.
Histological analysis
The liver specimens were fixed immediately in 4% para-
formaldehyde solution, buffered to pH 7.4, and embed-
ded in paraffin. Five-micrometer sections were cut and
stained with Masson's trichrome. The proportion of each
field displaying fibrosis was analyzed using computer
image analysis software (Image Pro Plus 4.0). Briefly,
regions of the section with the optical density characteris-
tics of fibrosis where counted and analyzed as a percent-
age of the total tissue. The total collagen surface density
was measured in 20 random fields at a magnification of
20× and is expressed as the percentage of total section
area.
ELISA for TGF-β
An ELISA kit (R&D Systems) was used to measure the
serum concentration of TGF-β following the manufac-
turer's protocol. The samples were activated by adding
200 μl in a tube with 200 μl of 2.5 M acetic acid, mixed,
incubated for 10 min at room temperature, and inacti-
vated with 200 μl of 2.7 M NaOH in 1 M HEPES. One
hundred microliters of the activated sample, negative con-
trol, and the standards were added to the plate in tripli-
cate. The absorbance was measured at 450 nm.
RNA extraction
Total RNA was extracted from a section of each liver
biopsy using Trizol (Invitrogen™) according to the manu-
facturer's instructions. The tissue was homogenized withBMC Gastroenterology 2009, 9:81 http://www.biomedcentral.com/1471-230X/9/81
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500 μl of Trizol. Chloroform (Sigma) was added and the
sample was centrifuged at 10,000 rpm at 4°C. The total
RNA was precipitated with isopropanol (Sigma). The RNA
pellet was washed with 75% ethanol and dissolved in
diethylene pyrocarbonate (DEPC) water. The final con-
centration and quality of RNA were determined by spec-
trophotometry, and the absorbance was measured at 260
and 280 nm.
Reverse transcription and real-time Polymerase chain 
reaction (PCR)
Total RNA was reverse transcribed to cDNA using Super-
Script III (Invitrogen™) enzyme. Two hundred nanograms
of total RNA, 1 μl of 10 mM dNTP mix, 1 μl of (0.125 μg/
μl) random primers, and DEPC water up to 13 μl were
incubated at 70°C for 5 min. Four microliters of 5× first-
strand buffer, 1 μl of 0.1 M DTT, 1 μl of RNaseOUT, and
1 μl of SuperScript III were added, and the samples were
incubated at 25°C for 5 min (annealing), at 50°C for 50
min (cDNA synthesis), and at 72°C for 15 min (enzyme
denaturation).
Real-time PCR was performed with an ABI Prism 7500
Sequence Detection System (Applied Biosystems). Two
microliters of cDNA was used in each PCR reaction. The
housekeeping gene 18S rRNA (Applied Biosystems) was
used for normalization and water was used as a no-tem-
plate control. The primers and probes (Applied Biosys-
tems) for the PCR reaction were those for the target genes
TGF-β, Col I, Col III, Col IV, PAI-1, and Smad7 (Table 1).
Each sample was analyzed in triplicate. Two microliters of
each cDNA sample was mixed with 7 μl of DEPC water, 10
μl of Universal Master Mix (Applied Biosystems), and 1 μl
of primer and probe (Applied Biosystems) of either the
housekeeping or the target gene. Twenty microliters of
this mixture was added to each well for each sample.
The relative quantification was calculated using the ΔΔCT
method. The mean CT of triplicate samples was used to
calculate the ΔCT as the difference in CT between the target
and reference gene. ΔCT for each sample minus the exper-
imental reference ΔCT control was expressed as the ΔΔCT.
The relative quantification is expressed as the fold expres-
sion of the target gene compared with the reference con-
trol expression according to the formula 2-ΔΔCT  and
expressed in relative expression units (REU).
Statistics
The results are expressed as mean ± SD. Student's t test was
used to analyze differences between groups, and the
Spearman (rs) correlation was used to analyze relation-
ships between variables. P values < 0.05 were considered
significant.
Results
Biochemical studies
The 14 BDI patients (10 women and 4 men) had a mean
age of 43.9 years (range, 17-65 years), and the 4 controls
(liver donors) had a mean age of 37.2 years (range, 21-61
years). The BDI patients had higher concentrations of the
aminotransferases, DB, and AP (Table 2).
Bismuth classification
According to the Bismuth classification method for iatro-
genic BDI[23], 11 patients were classified with lesion type
3, 2 with lesion type 2, and 1 with lesion type 1 (Table 2).
The lesion type did not correlate with the mRNA expres-
sion, with the extent of fibrosis, or serum TGF-β concen-
tration. Further experiments, with a larger patient group,
will be necessary to prove if the type or severity of BDI
does or does not influence the liver fibrosis process.
Liver fibrosis
Liver biopsies stained with Masson's trichrome stain
showed significant collagen levels in BDI patients (Figure
1B) we correlated collagen levels with increases in fibrosis.
Less of the ECM was stained in the livers of the controls
(Figure 1A). The morphometric analysis was correlated
with an average of 41.85% fibrosis in the BDI group com-
pared with 0.83% fibrosis in the control group (P = 0.001)
(Figure 2). The increase in collagen staining did not corre-
late with the lesion type in the BDI patient group, proba-
bly because of the variety of types in these patients. In the
morphological examination of liver biopsies from
patients, we observed cholestasis, fibrosis around portal
Table 1: Primers and probes of the genes studied
Gene GenBank
(Accession number)
Applied Biosystems ID Dye
18S rRNA -- FG 18S RNA VIC
TGF-β NM000660 HS00171257_m1 FAM
Col I NM000089 Hs00164099_m1 FAM
Col III NM000090 Hs00164103_m1 FAM
Col IV NM_001845 Hs00266237_m1 FAM
PAI-1 NM_000602 Hs00167155_m1 FAM
Smad7 NM005904 Hs00178696_m1 FAMBMC Gastroenterology 2009, 9:81 http://www.biomedcentral.com/1471-230X/9/81
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triad, proliferation of bile ducts and periportal inflamma-
tory infiltrate.
Serum TGF-β concentration
TGF-β concentration was measured in the PB of only 9 of
the 14 BDI patients because it was not possible to obtain
blood samples from all patients. Serum TGF-β concentra-
tion was significantly higher in the patients than in the
controls (Figure 3). The mean concentrations were 39 296
pg/ml (range, 15 565-65 194 pg/ml) in patients and 9008
pg/ml (range, 2622-20 880 pg/ml) in controls (P  =
0.005).
TGF-β, Smad7, Col I, Col III, Col IV, and PAI-1 gene 
expression
To evaluate the differential gene expression, we quantified
the level of TGF-β mRNA expression and its target genes,
Smad7, Col I, Col III, Col IV, and PAI-1 in both groups. The
mean TGF-β mRNA level was 11-fold higher in BDI
patients (11.59 REU) than in the controls (liver donors)
Table 2: Clinical and biochemical features of control and bile duct injury (BDI) patients groups
Group N Bismuth (lesion type) Time post-lesion (days) ALT
(0-45 UI/l)
AST
(0-41 UI/l)
DB
(0.1-0.4 mg/dl)
AP
(30-115 UI/l)
Control 1 0† 01 61 8 0 . 3 6 2 1
20 † 056 0 . 2 9 6 8
30 † 02 62 3 0 . 4 3 7 3
40 † 01 21 9 0 . 1 2 4 9
BDI 1 2 49 265 110 3.70 380
patients 2 1 2190 365 479 3.70 740
3 3 49 133 127 0.20 391
4 3 4 8 95 45 8 5 . 1 0 2 8 4
53 4 3 1 3 2 9 8 5 . 1 0 1 1 4
63 5 6 1 9 7 7 9 0 . 9 0 3 7 8
73N A 2 7 3 2 2 2 . 8 0 8 9 9
8 2 145 133 58 2.90 860
9 3 65 164 168 2.00 357
10 3 70 338 40 .01 489
11 3 42 285 85 6.20 806
12 3 1 106 95 23 320
13 3 1825 140 NA 0.90 306
14 3 56 222 117 NA 296
† = without lesion
NA = not available
Liver fibrosis Figure 1
Liver fibrosis. The liver section stained with Masson's trichrome from a control (A), compared with a BDI patient (B) showed 
significant deposition of ECM proteins (blue stain) in B.BMC Gastroenterology 2009, 9:81 http://www.biomedcentral.com/1471-230X/9/81
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(P = 0.138) (Figure 4A). Smad7 mRNA expression showed
a similar pattern: 6.69 REU in patients and 1.12 REU in
controls (P = 0.005) (Figure 4B).
Collagen mRNA expression was higher in the BDI group.
The mean level of Col I mRNA was 26.86 REU in patients
and 1.35 REU in controls (P = 0.012) (Figure 4C). The BDI
patients showed a homogeneous pattern of Col III, mRNA
expression (mean 18.84 REU) (Figure 4D). Col IV (mean
11.77 REU; Figure 4E) and PAI-1 (mean 22.18 REU, P =
0.001; Figure 4F) were also overexpressed in BDI patients.
The Spearman (rs) correlation showed that the Smad7
mRNA level correlated positively with the level of TGF-β,
Col I, and Col III, mRNA (Table 3). As expected, the
mRNA expression of all analyzed genes, except for Col IV,
correlated significantly with the increase in serum TGF-β
concentration (data not shown), probably because of the
direct influence of TGF-β signaling on the expression of
ECM proteins.
Discussion
BDI causes biliary acid flow obstruction, increases bile
deposition in hepatic tissue, and causes hepatocyte degen-
eration, cell death, and release of liver enzymes such as
aminotransferases and AP. Additionally, inflammatory
cells migrate to the injured tissue, which contributes to
secondary biliary cirrhosis[7,8].
TGF-β is a pleiotropic molecule involved in ECM proteins
expression in fibrogenesis[24,25]. There is some contro-
versy about whether the serum TGF-β concentration can
be correlated with hepatic injury in different liver dis-
eases[26,27]. Despite this controversy, we found that BDI
patients have increased serum concentrations of this pro-
tein, perhaps reflecting the overexpression of this cytokine
in the liver. mRNA TGF-β expression also increases in rat
liver cholestasis[20,28].
Dooley et al[20] demonstrated that Smad7 (overexpressed
through an adenovirus containing Smad7 cDNA) inhibits
TGF-β signal transduction and influences the extent of
fibrosis when used as preventive therapy in a bile duct
ligation (BDL) model of fibrosis. These results suggest that
Smad7 is a potential therapeutic tool for liver fibrosis and
cirrhosis. The aim of our study was to determine whether
Smad7 expression correlates with the gene expression of
TGF-β, Col I, Col III, Col IV, and PAI-1 in patients with
liver fibrosis caused by BDI.
Tahashi et al[16] showed that Smad7 protein has a critical
role in acute and chronic liver injury and that the amount
of this protein increases in acute and decreases in chronic
liver injury, along with an associated decrease in collagen
expression. Our results showing increased Smad7 mRNA
Percent optical density of collagen staining Figure 2
Percent optical density of collagen staining. Morpho-
metric analysis demonstrates more fibrosis in a liver section 
from BDI patients, who had an average of 41.85% fibrosis in 
liver tissue, which differed significantly from the percentage 
in the control group.
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mRNA expression of TGF-β and gene targets by real-time PCR Figure 4
mRNA expression of TGF-β and gene targets by real-time PCR. TGF-β (A), Smad7 (B), Col II (C), Col III, (D), Col IV 
(E), and PAI-1 (F) mRNA levels were higher in BDI patients than in controls, although the differences were significant only for 
Smad7, Col I, and PAI-1 expression.
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expression along with the collagens I, III and IV seem to
contradict those of Tahashi et al. However, they used a
CCl4 model that produces damage similar to that caused
by alcohol in humans and not a BDL model.
We found that TGF-β  mRNA expression was 11-fold
higher in BDI patients than in liver donors. This contrasts
with a 6-fold higher Smad7  expression level in BDI
patients. An increase in the expression of Smad7 must cor-
relate with a reduction of the expression of fibrogenic
molecules because of the direct negative feedback in TGF-
β signaling. Although we found higher Smad7 mRNA
expression in patients, expression of the mRNA for colla-
gens and PAI-1 also increased, demonstrating that Smad7
expression is not enough to inhibit TGF-β signaling. These
results are similar to those reported recently by Seyhan et
al[29] who found continuous Smad7 augmentation along
with liver fibrosis cholestasis induced in an experimental
rat model was insufficient to blunt fibrogenesis. This
result may reflect the observation that the transcriptional
regulation of ECM proteins can be directed through
another TGF-β dependent pathway[30], such as connec-
tive tissue growth factor (CTGF), a growth factor that is
recognized as a fibrogenic molecule in the liver[31,32].
Smad7 expression is regulated by two mechanisms: tran-
scription and protein degradation[33]. The Smad7 tran-
scriptional regulation is mediated by the Ski protein,
which inhibits the Smad7 promoter, and the posttrans-
ductional regulation is mediated through the effects of
Smurf and Jab1 proteins, which promote Smad7 degrada-
tion[34,35].
We found a strong positive correlation of Smad7 mRNA
expression with TGF-β, Col I and Col III mRNA expres-
sion. The mRNA expression levels were 6.69, 11.59,
26.86, and 18.84 REU, respectively. We also observed a
significant amount of fibrotic tissue deposition in the liver
biopsies of BDI patients. In the literature, there is one
report on increased Smad7 levels in tissue biopsies[36]. In
this study, we were limited to analyzing only mRNA
expression, and the expression of Smad7 and of ECM pro-
teins need to be measured in BDI patients.
We emphasize that most of the information about the
fibrotic process and the molecules involved had been
obtained from experimental models (animals and cell
cultures). This is the first work in humans to focus on the
mRNA expression of ECM proteins and their relationship
to Smad7.
The clinical parameters of biliary obstruction evaluated in
the patients (AST, ALT, DB, and ALP concentrations) did
not correlate with the gene expression levels, serum TGF-
β concentration, or fibrosis percentage. We found no cor-
relation between the lesion type and fibrosis percentage.
Type 3 lesion was the most frequent lesion in the patients
(11 from 14), but this type was not related to the mRNA
expression or liver fibrosis.
Additionally, gene polymorphisms of TGF-β (non coding
-509 C/T and coding codon 10, codon 25, codon 263)
have been associated with modified serum levels of this
cytokine in different diseases [37-39]. We showed
increased serum levels of TGF-β in patients with BDI. In
this study, we did not evaluate any of the TGF-β polymor-
phisms. It will be important to plan further studies to
determine if serum TGF-β levels are more affected by the
polymorphisms rather than the presence of bile duct
injury.
A recent report demonstrated the predominance of a sin-
gle nucleotide polymorphism at codon 25 in cirrhotic, but
not healthy subjects of Mexican origin[40]. It will also be
interesting to determine if there exists a strong relation-
ship between Smad7 and TGF-β dependent genes such as
collagens, PAI-1, TIMPs, and others that lead to extracellu-
lar matrix deposition in patients with different polymor-
phisms for TGF-β.
Conclusion
We found augmented serum concentration of TGF-β and
an increase in the percentage of fibrotic tissue in the liver
of BDI patients. Contrary to expected results, the 6-fold
increase in Smad7 expression did not inhibit the expres-
sion of TGF-β, collagens, and PAI-1. We also observed
greater expression of Col I and Col III mRNA in BDI
patients and significant correlations between their expres-
sion and TGF-β concentration and Smad7 mRNA expres-
sion.
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